Skip to Content

Baqsimi Approval History

FDA Approved: Yes (First approved July 24, 2019)
Brand name: Baqsimi
Generic name: glucagon
Dosage form: Nasal Powder
Company: Eli Lilly and Company
Treatment for: Hypoglycemia

Baqsimi (glucagon) is a nasally administered antihypoglycemic agent indicated for the treatment of severe hypoglycemia in diabetes patients ages 4 years and older.

Development History and FDA Approval Process for Baqsimi

DateArticle
Jul 24, 2019Approval FDA Approves Baqsimi (glucagon) Nasal Powder for the Treatment of Severe Hypoglycemia

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide